The continuous bioprocessing market enables efficient and cost-effective production of biologics. Continuous bioprocessing technologies facilitate uninterrupted manufacturing of biologic drugs using living cells or components in a bioreactor. This eliminates costly and time-consuming batch manufacturing methods.
The Continuous Bioprocessing Market is estimated to be valued at US$ 395 Mn in 2024 and is expected to exhibit a CAGR of 8.4% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the continuous bioprocessing market are AGC Biologics, Biogen, Bristol-Myers Squibb, Sanofi Genzyme, FUJIFILM Diosynth Biotechnologies and Among Others. Key players like AGC Biologics are developing integrated continuous bioprocessing platforms to help drug manufacturers maximize production output.
The rising prevalence of chronic diseases is driving up demand for biologics globally. This has necessitated better and more efficient biomanufacturing techniques like continuous bioprocessing. Continuous bioprocessing ensures a steady supply of biologics to meet this growing demand.
Leading biomanufacturers are expanding their continuous bioprocessing facilities globally to cater to the diverse regulatory demands. For instance, Bristol-Myers Squibb is setting up a continuous bioprocessing plant in Europe. Such expansions will help address the growing demand for biologics worldwide.
Market Key Trends
Automation is a key trend in the continuous bioprocessing market. Fully automated and integrated continuous manufacturing platforms minimize human errors and improve production consistency. Players are developing systems with automated material handling, self-learning controls and remote process monitoring capabilities. This boosts productivity and brings more efficiency compared to traditional batch processes. Technologies like model predictive control and machine learning are being incorporated for advanced process automation in continuous bioprocessing.
Porter’s Analysis
Threat of new entrants: High capital requirement act as a barrier for new players.
Bargaining power of buyers: Large pharmaceutical companies have strong bargaining power over suppliers due to their huge demand.
Bargaining power of suppliers: Suppliers have limited bargaining power as there are many solution providers.
Threat of new substitutes: Substitutes are less likely as products produced through continuous bioprocessing have distinct advantages.
Competitive rivalry: Intense competition among existing players to gain higher market share.
Geographical Regions
North America accounted for the largest share of the continuous bioprocessing market in 2024. High adoption of advanced technologies, presence of major biopharma players, and availability of government and private funding are factors driving the market in this region.
Asia Pacific region is expected to witness the highest growth during the forecast period. Expanding biopharmaceutical industry, rising disease prevalence, increasing government support for healthcare infrastructure development, and growing investments by major companies in emerging Asian countries are expected to boost the market.
What Are The Key Data Covered In This Continuous Bioprocessing Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Continuous Bioprocessing’s growth between 2024 and 2031.
:- Accurate calculation of the size of the Continuous Bioprocessing and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Continuous Bioprocessing Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Continuous Bioprocessing vendors
FAQ’s
Q.1 What are the main factors influencing the Continuous Bioprocessing?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Continuous Bioprocessing companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Continuous Bioprocessing’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Ravina Pandya
Ravina Pandya,a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals. LinkedIn Profile